Skip to main content
. 2021 Jan 7;16(8):1660–1670. doi: 10.4103/1673-5374.303045

Figure 2.

Figure 2

Effects of exendin-4 and DA-CH5 on the viability of 6-OHDA-treated SH-SY5Y cells as detected by the MTT assay.

(A) 6-OHDA treatment induced neuronal death in a dose-dependent manner. (B) Cells were exposed to 350 µM 6-OHDA with or without 100 nM of exendin-4 or DA-CH5 for 24 hours. Exendin-4 and DA-CH5 prevented 6-OHDA-induced neuronal death. Data are expressed as the mean ± SD. The experiments were repeated four (A) or five (B) times. **P < 0.01, ***P < 0.001, vs. control group (CON); ###P < 0.001, vs. 150 µM 6-OHDA group; &&&P < 0.001, vs. 250 µM 6-OHDA group; †P < 0.05, †††P < 0.001, vs. 350 µM 6-OHDA group; §§P < 0.01, vs. 350 6-OHDA + exendin-4 group (one-way analysis of variance followed by Tukey’s multiple comparison test). 6-OHDA: 6-Hydroxydopamine; exendin-4 and DA-CH5: glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide; PD: Parkinson’s disease.